Cytokine fusion proteins and uses thereof
AssigneeAnwita Biosciences, Inc.
InventorsZiyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang, Eric Liao, Ella Li
Life of this patent
Estimating the term…
Abstract
The present application provides fusion proteins that comprise a cytokine fused to an albumin binding moiety. The fusion proteins may further comprise an antigen binding moiety such as a therapeutic antibody. The present application also provides methods of making and using the fusion proteins. The present application also provides methods of treatment comprises administering a fusion protein comprising a cytokine fused to a half-life extending domain and a second agent.
Claims30
A fusion protein comprising:
- a) a cytokine, and b) an albumin binding moiety, wherein the cytokine is selected from the group consisting of IL-21, IL-7, IL-15, IL-15 bound to IL-15Rα or fragment thereof, IL-33, and IL-22.
A fusion protein comprising:
- a) a cytokine fused to an albumin binding moiety (“cytokine-ALBBM”), and b) an antigen binding moiety, wherein the linkage between the cytokine-ALBBM and the antigen binding moiety is optionally cleavable.
10-12. (canceled)
15-16. (canceled)
19-20. (canceled)
22-23. (canceled)
A method of treating a disease or condition in an individual comprising administering to the individual a) a fusion protein comprising i) a cytokine and ii) a half-life extending domain fused to the cytokine;
- and b) a second agent.
(canceled)
31-32. (canceled)
34-44. (canceled)
46-47. (canceled)
Dependencies are inferred from the claim text.